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FB: Please, provide us with some 
information on your background and 
professional experience.
DW: I was born and raised in The 
Netherlands. Being the only child in the 
family, reading was my passion. 
At an early age I became inspired by a book1 written by 
Dr Albert Schweitzer, with stories about his hospital in 
Lambarene, now Gabon. With that in mind, I studied 
Medicine at the University of  Amsterdam in The Netherlands 
and specialized in tropical infectious diseases; subsequently I 
completed a Masters in Tropical Paediatrics at the Liverpool 
School of  Tropical Medicine.
I gained my first work experience as a medical coordinator 
with Medecins Sans Frontieres (MSF). During my work with 
MSF in Lebanon (1987/88), I was confronted with several 
active cases of  vaccine-preventable diseases in children living 
in the Israeli occupied zone of  Southern Lebanon. With 
the support of  the International Red Cross, we acquired 
permission to enter the restricted area and subsequently 
were able to organize for the vaccination of  all the children 
in the region, over a period of  3 months.
During my assignment with MSF in Afghanistan (1989/91), 
I coordinated a measles vaccination campaign during a 
“cross-border” mission in the Russian occupied province of  
South Kabul.
In 1992 I finally made it to Africa, where we worked alongside 
the United Nations High Commissioner for Refugees 
(UNHCR) to set-up a medical aid program, including 
vaccinations, for the Mauritanian refugees in Senegal.
My last mission with MSF in Mozambique brought me into 
contact with Malawi. Travelling over land in Mozambique 
at that time was very unsafe. The Frelimo/Renamo conflict 
was at its peak and mines were littered all over the country. 
Therefore, the safest way of  travelling was by plane, a small 
Cessna operated by “Save the Children”, which used Blantyre 
as its base…the beginning of  the Malawi connection!
In the Nineties, many Districts in Malawi were headed by a 
Dutch District Health Officer (DHO) as part of  a bilateral 
aid program between the Dutch and Malawi Governments. I 
worked for 2 years in this program, first as a Medical Officer 
in the Surgical, Obstetrics and Gynaecology and Paediatric 
Departments of  Queen Elizabeth Central Hospital, and 
subsequently 3 years as a DHO in Mulanje District, which 
still included Phalombe then. It was a challenging time with 
HIV emerging, causing havoc and devastation in the work 
force and straining the hospital resources to the maximum. 
The Government initiated the co-ordination with Non-
Governmental Organisations and the Christian Hospital 
Association of  Malawi (CHAM), in order to develop and 
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implement an integrated public health care program, based 
on the Health Delivery Area concept.
As the Public Health services in the District were very 
much an integral part of  the DHO’s responsibilities, I still 
have vivid memories of  the ‘Wednesday District’ visits: 
setting off  at dawn and returning far after dark, with the 
dedicated members of  the District Health Management 
Team, delivering anything from vaccines, paraffin/gas-
bottles for maintenance of  the cold chain, salaries, drugs, 
delivery kits, family planning (then still called child-spacing) 
materials, chlorine tablets, food stuffs and so on, to the far 
corners of  the District. We would return to the hospital late 
at night, with cases of  obstructive labour and other medical 
emergencies in the back of  the car. The road was bumpy 
which would often see the obstructive labour cases develop 
into successful deliveries (under a chitenje, in order to keep 
the delivery protected from the inquisitive eyes from people 
in the evening bus coming from Blantyre!).
In 1997 I left Mulanje District to go and pursue a Masters 
in Liverpool. I undertook my dissertation research 
(“Micronutrients in breast milk and blood of  lactating 
women”) in Thailand.
Asia, in many respects, turned out to be a world of  difference 
compared to Africa and I enjoyed the experience of  working 
there. The enchantment however of  the African continent 
brought me back to Malawi, where I was fortunate to be 
given the opportunity to start off  with two new careers: one 
as a researcher, and one as a mother of  twins!
Following my earlier adventures in implementing vaccine 
programmes, I developed a long- term research interest in 
vaccine-preventable diseases. Back in Malawi, I was entrusted 
to become the country Principal Investigator of  three large 
clinical trials under the auspices of  the University of  Malawi, 
College of  Medicine and University of  Liverpool:In 2002, I 
conducted a measles vaccine trial, in collaboration with the 
Centers for Disease Control and Prevention (CDC) Atlanta, 
the London School of  Hygiene & Tropical Medicine 
(LSHTM) and the World Health Organization (WHO). 
This study evaluated the serological response to two doses 
of  standard titre measles vaccine in HIV infected and –
uninfected infants in Malawi2.
In 2007, Malawi participated in the pivoting and exciting 
Phase III clinical trial of  rotavirus vaccine6,7 and more 
recently we completed a Phase II study of  the candidate 
RTS,S vaccine against malaria, an assessment of  the safety 
and immunogenicity of  7 dosing regimens in neonates and 
infants in Blantyre.
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FB: Tell us about rotavirus.
DW: Rotavirus diarrhoea kills almost half  a million infants 
and young children each year3. Over 90% of  these deaths 
occur in developing countries, where access to simple, 
lifesaving treatment is limited4,5. Rotavirus is found 
everywhere, regardless of  hygienic conditions, and almost 
all children will have suffered from a rotavirus infection by 
the time they reach the age of  5 years. Since improvement 
in sanitation and hygiene will not substantially decrease the 
incidence of  rotavirus disease, the prevention of  childhood 
deaths caused by rotavirus infections will mainly require the 
use of  rotavirus vaccines.
FB: What is the name of  the rotavaccine and how was it 
introduced in Malawi?
DW: Between 2006 and 2009, a Phase III clinical trial of  
GlaxoSmithKline’s human rotavirus vaccine RotarixTM was 
conducted in Blantyre, Malawi and in South-Africa6,7. The 
rationale of  the trial was to assess the efficacy, safety and 
immunogenicity of  the vaccine. Despite a high background 
rate of  natural rotavirus infection and a wide diversity of  
circulating rotavirus strains, RotarixTM reduced severe 
rotavirus gastroenteritis episodes by about half. Although 
the vaccine efficacy is lower in African countries when 
compared to Europe or the Americas, the vaccine prevents 
more rotavirus diarrhoea episodes in Africa because of  a 
higher rate of  severe disease in this part of  the world: the 
glass of  preventing severe episodes of  rotavirus diarrhoea 
might be only half-full, but the ultimate effect depends on 
how big the glass really is!
Following consideration of  the results from the combined 
Malawi and South-Africa trials, the WHO recommended in 
June 2009 to include oral rotavirus vaccines in all countries’ 
national childhood immunization programs8. This was a 
tremendous milestone in ensuring that vaccines against the 
most common cause of  lethal diarrhoea reach the children 
who need them most. The Malawi Ministry of  Health applied 
for GAVI (Global Alliance for Vaccines and Immunization) 
funding and in 2012 the RotarixTM vaccine was introduced 
into the national immunization-program in Malawi, free of  
charge for all infants in Malawi.
FB: What can you say about the impact of  the rotavirus 
vaccination program in Malawi?
DW: A study on the effectiveness of  Rotavirus vaccine in 
Malawi has found that the risk of  diarrhoea and the number 
of  hospital admissions due to severe diarrhoea among 
infants have reduced by 64 and 43% respectively, since the 
introduction of  the rota-vaccine in 20129. The rotavirus 
vaccine is found to be highly cost-effective in Malawi and 
giving the vaccine to children can lower illness costs to 
families10,11.
FB: What challenges, in general, do you experience in 
your work as a clinical researcher in Malawi?
DW: Vaccine clinical trials are usually studies recruiting 
healthy children and taking blood samples is an integral part 
of  the trial. There is no problem with taking a small amount 
of  blood in the context of  sick children in hospital but the 
acceptability of  collecting blood samples from healthy infants 
in the community is quite a challenge! People in Malawi, like in 
many other countries in Africa, do not like blood being taken 
from their children, especially not when it concerns babies 
and infants. The blood volume needed for antibody testing 
in these vaccine trials is not much, usually not more than 1ml 
but the entire procedure, including a needle and the baby 
crying is not what any mother likes. We need to establish a 
very good understanding with the mothers, their families and 
the community, to explain and make them understand why 
and for what reason we need to take a blood sample from 
their babies, three or four times over the course of  the study. 
Without the mother’s understanding and trust, accusations 
may arise from the community towards the clinical team 
of  selling the blood, or using it for witchcraft, which may 
jeopardize the recruitment and retention of  children in the 
trial. Blood in Malawi is always a more delicate issue than we 
tend to assume.
FB: What other studies are you currently doing or are 
planning to do?
DW: There are two studies coming up soon. One is the 
“ABCD Study”: AntiBiotic treatment of  moderate to severe 
Childhood Diarrhoea. This study is a WHO-sponsored multi-
country randomized double-blinded trial of  a 3-day course 
of  azithromycin versus placebo. It is planning to recruit 
in total 11,500 children in 7 countries: Malawi, Tanzania, 
Kenya, Mali, Bangladesh, Pakistan and India. Mortality 
among young children with non-dysenteric diarrhoea in 
developing countries is high12. Multi-country evidence shows 
that bacterial pathogens contribute to childhood diarrhoea 
and mortality12. In Malawi, existing VacSurv surveillance9,10,11 
in the post-rotavirus vaccine era shows a substantial 
mortality at home among children discharged after having 
been hospitalised with diarrhoea. Traditionally, according to 
WHO Integrated Management of  Childhood Illness (IMCI) 
Guidelines, antibiotics were reserved for diarrhoea due to 
cholera or for dysentery. The hypothesis of  the ABCD study 
is that antibiotic therapy is going to reduce mortality and 
improve growth even in non-dysenteric diarrhoea.
The second study which is forthcoming is the “RV3” oral 
rotavirus vaccine study: A Phase II randomised double 
blind dose-ranging study of  the RV3 Rotavirus Vaccine 
administered as a 3 dose neonate or infant schedule. The 
sponsor for this trial is the Murdoch Children’s Research 
Institute (MCRI) in Melbourne, Australia. The RV3 rotavirus 
vaccine has been developed from a naturally occurring strain 
of  rotavirus (RV3) found in healthy babies in an obstetric 
hospital nursery in Melbourne13. The special feature of  this 
strain of  Rotavirus is that it did not cause any disease in 
these babies. The goal of  the RV3 Program is to develop an 
effective, affordable rotavirus vaccine aimed at prevention 
of  rotavirus disease from birth14,15. Administration of  the 
RV3 vaccine at birth may offer earlier protection for infants 
in developing countries than the currently licensed rotavirus 
vaccines.
FB: What can you say is your greatest achievement – 
one that you are most proud of  in your life?
DW: It is difficult to pick out one particular thing. There are 
a few things that I am proud of  in both my personal and 
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professional life….like becoming a mother and being able to 
see my healthy twin- boys grow and develop into young men, 
respecting all living things as they do. I am equally proud of  
my mother who turned 100 years last year! She is still very 
sharp and every evening, for the last 20 years, calls us from 
The Netherlands, to keep up to date with our endeavours on 
this side of  the world.
From a professional point of  view I think the most exciting 
thing was taking part in the Rotavirus vaccine study and the 
subsequent WHO recommendation to include the vaccine in 
all countries’ national childhood immunization programs. It 
is a privilege and feels good to be able to contribute a small 
piece to the enhancement of  children’s lives here.
FB: Any last words?
DW: I have been in Malawi for about 20 years now and it is 
a real pleasure to be able to live in a country as beautiful and 
as peaceful as Malawi. I am still working together with the 
same wonderful team of  people I have worked with during 
the last 3 clinical trials. Malawians make a great team; if  you 
motivate them, they will more than motivate you in return. 
They are, you know, people that are really having the warm 
heart of  Africa in the right place!
I would like to finish with a quote by Dr Albert Schweitzer: 
“Success is not the key to happiness. Happiness is the key 
to success. If  you love what you are doing, you will be 
successful”.
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